Dvorit Samid

Dr. Samid joined Aardvark in 2020, bringing over 3 decades of experience in taking novel drugs from discovery, through clinical development and commercialization. Prior to joining Aardvark, Dr. Samid lead Medical Affairs of other pharmaceutical companies including Hoffman-La Roche, ImClone/Lilly, Abraxis, and NantKwest. She served also as an Associate Professor at the University of Virginia’s Medical School and as Section Chief at the National Cancer Institute. Dr. Samid holds 19 patents and has published over 80 papers in peer-reviewed journals.